Using Chemerin and Inflammation Markers to Predict Coronary Ar-tery Disease in Metabolic Syndrome Patients

Abstract

The systemic inflammation plays a role in both metabolic syndrome (MetS) and coronary artery disease (CAD). This study was undertaken to determine chemerin's role and inflammation indicators in the emergence of CAD in MetS patients. The study was conducted on 120 subjects (male and female), whose ages (35 to 65)years. The study subjects divided into three groups which are 45 MetS patients with CAD and 40 MetS patients without CAD, and 25 control, who underwent coronary angiography for the evaluation of CAD. The chemerin level, as well as the levels of inflammatory markers such as interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), leptin, and tumor necrosis factor-alpha (TNF-α), were measured by enzyme-linked immunosorbent assay (ELIZA). The results show that the concentrations of chemerin, TNF-α, leptin, and Il-6 were significantly elevated in MetS patients with CAD compared with control group. Triglycerides, cholesterol, and LDL-C were significantly increased, while HDL-C was significantly decreased in MetS patients compared with control. The present study show that chemerin is associated with markers of inflammation and predictors such as IL-6, hs-CRP and TNF-alpha, which important risk factors determining CAD in Iraqi subjects with MetS. Adipokines might also be seen as crucial clinical biomarkers and pharmacological targets for lowering the mortality and incidence of CAD in MetS patients.